Study 2 of 1024 for search of: Japan
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Xeloda vs. TS-1 as First-Line Treatment in Unresectable or Recurrent Breast Cancer
This study is currently recruiting participants.
Verified by Japan Breast Cancer Research Network, August 2008
Sponsored by: Japan Breast Cancer Research Network
Information provided by: Japan Breast Cancer Research Network
ClinicalTrials.gov Identifier: NCT00438100
  Purpose

To investigate and compare the efficacy and safety of TS-1 vs. Xeloda as primary chemotherapy in patients with inoperable or recurrent breast cancer.


Condition Intervention Phase
Breast Neoplasms
Drug: Capecitabine
Drug: TS-1
Phase II

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer
Drug Information available for: Capecitabine S 1 (Combination)
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Randomized Control Study of Xeloda Alone vs. TS-1 Alone as First-Line Treatment in Unresectable or Recurrent Breast Cancer Patients

Further study details as provided by Japan Breast Cancer Research Network:

Primary Outcome Measures:
  • Time to disease progression [ Time Frame: The follow up period will be five years after the last dose has been administered. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adverse events [ Time Frame: The follow up period will be five years after the last dose has been administered. ] [ Designated as safety issue: Yes ]
  • Antitumor effects [ Time Frame: The follow up period will be five years after the last dose has been administered. ] [ Designated as safety issue: No ]
  • Time to treatment failure [ Time Frame: The follow up period will be five years after the last dose has been administered. ] [ Designated as safety issue: Yes ]
  • Survival rate [ Time Frame: The follow up period will be five years after the last dose has been administered. ] [ Designated as safety issue: No ]

Estimated Enrollment: 220
Study Start Date: May 2007
Estimated Study Completion Date: May 2024
Estimated Primary Completion Date: May 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A: Active Comparator
Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
Drug: Capecitabine
1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
B: Experimental
TS-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.
Drug: TS-1
80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.

Detailed Description:

The incidence of breast cancer is increasing in Japan: 33,676 women were diagnosed with breast cancer in 2001, making it the leading cause of cancer among women since 1995. Statistical database in Exel format/outline of health welfare statistics from the Ministry of Labor, Health, and Welfare show that the number of deaths from breast cancer was 9,806 in 2003. Because the ten-year survival rate is about ninety percent in Stages 0 and I breast cancer patients, detection and treatment at an earlier stage can lead to higher survival rates. However, the recurrence rate increases as the disease progresses. In addition, about thirty percent of all breast cancer patients are believed to have recurrent disease. Thus, developing treatments against recurrence may be an important task.

The Guideline for Breast Cancer Treatment, 2004 version, recommends chemotherapy, including anthracyclines or taxanes as a first-line chemotherapy for metastatic or recurrent (grade B recommendation) breast cancer. In a second-line therapy recommended for metastatic or recurrent diseases, the Guideline reports that a combination of capecitabine, a 5Fu derivative (an oral chemotherapy of pyrimidine fluorides approved in 2003) with docetaxel is superior to docetaxel alone for improving survival. This regimen is recommended for patients with cardiac malfunction who cannot be treated with anthracyclines (grade B recommendation). However, data are lacking to support capecitabine as a standard regimen as a second-line therapy; its efficacy needs verification and further study. Accordingly, this study is designed to investigate the efficacy and safety of TS-1 alone, an oral pyrimidine fluoride, to which an indication of "inoperable or recurrent breast cancer" was added, as a first-line therapy in patients with inoperable or recurrent breast cancer by comparing it with Xeloda (capecitabine) alone, which is already approved of the same indication.

  Eligibility

Ages Eligible for Study:   25 Years to 74 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biopsy-diagnosed breast cancer with metastasis in multiple organs
  • Performance Status (World Health Organization :WHO) 0-2
  • Functions below are maintained in major organs:

    • Leukocyte count: 4,000/mm3 to 12,000/mm3
    • Neutrophil count: >2,000/mm3 or more
    • Platelet count: <100,000/mm3 or more
    • Hemoglobin: >9.5 g/dL
    • Total bilirubin: >1.5 mg/dL
    • AST(GOT): within twice a normal upper value in an institution
    • AST(GPT): within twice a normal upper value in an institution
    • BUN: < 25 mg/dL
    • Creatinine: within a normal upper value in the institution
    • 24 hours creatinine clearance: >50 mL/min (using the Cockcroft-Gault formula)
    • Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85
  • Written informed consent will be obtained for patients for entering this study

Exclusion Criteria:

  • Patients with synchronous multiple cancers
  • Complicated with infection
  • Fever from suspected infection
  • Metastasis to the central nerve system
  • A history of ischemic cardiac diseases
  • Active gastrointestinal ulcer
  • Severe nerve disorder
  • Women who are potentially pregnant, pregnant, or breast-feeding
  • Severe drug allergy
  • Severe suppression of the bone marrow
  • Severe renal disorder
  • Being treated with other pyrimidine fluoride antineoplastic agents (including any combination therapy)
  • Being treated with flucytosine
  • Complicated with the infection onset which a study doctor assesses to be inappropriate for this study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00438100

Contacts
Contact: Satoru Iwase, MD 81-3-3815-5411 ext 37417 iwases-rad@umin.ac.jp

Locations
Japan
Kansai Medical University Hirakata Hospital Recruiting
Hirakata, Japan, 573-1191
Hirosaki University Hospital Recruiting
Hirosaki, Japan, 036-8563 
The University of Tokyo Hospital Suspended
Tokyo, Japan, 113-8655
Kyushu Central Hospital Recruiting
Fukuoka, Japan, 815-8588
Shinyahashiradai Hospital Suspended
Matsudo, Japan, 270-2253
Hiroshima University Hospital Suspended
Hiroshima, Japan, 734-8551
Nagumo Clinic Recruiting
Tokyo, Japan, 141-0032
Sponsors and Collaborators
Japan Breast Cancer Research Network
Investigators
Principal Investigator: Daigo Yamamoto, MD Department of Surgery, Kansai Medical University Hirakata Hospital
  More Information

Informations about study group, Japanese Breast Cancer Research Network (JBCRN) and ongoing and planned clinical trials. In Japanese and password locked.  This link exits the ClinicalTrials.gov site

Responsible Party: Japan Breast Cancer Research Network ( Japan Breast Cancer Research Network )
Study ID Numbers: JBCRN-05, UMIN000000609
Study First Received: February 18, 2007
Last Updated: August 24, 2008
ClinicalTrials.gov Identifier: NCT00438100  
Health Authority: Japan: Institutional Review Board

Keywords provided by Japan Breast Cancer Research Network:
Breast Neoplasms
Drug Therapy

Study placed in the following topic categories:
Capecitabine
Skin Diseases
Breast Neoplasms
Breast Diseases
Recurrence

Additional relevant MeSH terms:
Antimetabolites
Neoplasms
Antimetabolites, Antineoplastic
Neoplasms by Site
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009